Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Australia Wine Exports Fall in 2025 as Global Drinking Declines and China Demand Weakens 
U.S. Stock Index Futures Steady as Fed Decision and Big Tech Earnings Loom 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
Oil Prices Hit Four-Month High as Geopolitical Risks and Supply Disruptions Intensify 
Thailand Moves to Regulate Gold Trading to Curb Baht Strength and Support Economic Growth 
Australia Inflation Surprise Fuels Rate Hike Expectations Ahead of RBA Meeting 
Asian Currencies Slip as Dollar Rebounds Ahead of Fed Rate Decision 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Samsung Biologics is said to be most likely to sign a deal with Moderna, an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The contract is for the production of COVID-19 vaccine in South Korea.
Samsung and Moderna’s anticipated announcement
As per The Korea Herald, Samsung Biologics and Moderna may work together to boost vaccine production amid the vaccine shortage in the country. It was reported that the two companies may formally announce their deal at the summit where S. Korea’s President Moon Jae In and US President Joe Biden are set to meet.
A local TV station was said to have reported about the possibility of this business negotiation last weekend. Other media outlets followed suit and shared related reports.
In any case, Samsung Biologics did not confirm if it will indeed sign a contract with Moderna for vaccine production and supply. It was quite vague as the Incheon-based biotechnology company did not deny the reports as well. In a regulatory filing, there was a statement saying there is no decision yet about Moderna’s COVID-19 being manufactured in S. Korea.
The guessing game
There have been lots of reports as to which company that Moderna will partner with as it is reported to be very interested in producing its vaccine in the said Asian region. Various firms were mentioned, and initial rumor is that it will work with Hanmi Pharmaceuticals or GC Pharma.
And now, the most promising candidate for a deal with Moderna is reportedly Samsung Biologics that was suddenly added to the list of potential partners. Moderna’s CEO, Stephane Bancel, may visit S. Korea this month to survey as per the reports.
Maeil Business News pointed out that it was also reported earlier that Samsung Biologics will produce Pfizer vaccine but this was vehemently denied but with Moderna, it was different as the Korean firm would not acknowledge or deny and only saying that “nothing has been finalized yet.”
Thus, it was speculated that Samsung Biologics and Moderna are more likely to confirm their contract soon. The rumors of the partnership were heightened by the fact that the American pharma already started looking for senior executives for its office that will soon open in Korea.
